Elsevier Launches New Open Access Journal: Leukemia Research Reports
A new forum for short communications of clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies
Oxford, November 22, 2012 – Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new open access, online journal, Leukemia Research Reports.
Leukemia Research Reports, a sister journal to the prestigious publication Leukemia Research, will deliver timely information online to all health care professionals involved in basic and/or applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. It will fulfill this role by rapidly publishing a range of peer-reviewed short form papers, including brief communications, case reports, letters to the editors, images and debate articles.
The editors of Leukemia Research Reports are: Dr Suneel Mundle (Janssen Services LLC and Rush Medical College, Chicago, IL) and Dr Meir Wetzler (State University of New York at Buffalo School of Medicine and Roswell Park Cancer Center, Buffalo, NY).
The editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies. Coverage will encompass the application of oncogenes, genomics (gene expression profiles, microRNAs), proteomics growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition articles are solicited on the rapidly growing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms.
For more information or to submit an article, go to http://www.journals.elsevier.com/leukemia-research-reports. First articles published in the journal are now available online through ScienceDirect.
# # #About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
+44 1865 843113